Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Crowley

Showing results (11-20 of 178) with videos related to

Pageof 18
Sort By:
Biometrics|July 14, 2005
Adaptive risk group refinementMichael LeBlanc, James Moon, John Crowley
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 8, 2010
Seamless phase I-II trial design for assessing toxicity and efficacy for targeted agentsAntje Hoering, Mike LeBlanc, John Crowley
Clinical Trials (London, England)|February 20, 2008
Interim futility analysis with intermediate endpointsBryan Goldman, Michael LeBlanc, John Crowley
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 28, 2008
Big question, small answerTony S K Mok, John Crowley
Current Oncology Reports|August 22, 2012
The automatic clinical trial: leveraging the electronic medical record in multisite cancer clinical trialsKeith Goodman, Judy Krueger, John Crowley
The New England Journal of Medicine|July 11, 2008
Duration of survival in patients with myeloma treated with thalidomideBart Barlogie, John D Shaughnessy, John Crowley
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 28, 2009
We probably have the answer: now what is the question?Peter Goldstraw, Ramón Rami-Porta, John Crowley
Nature Reviews. Drug Discovery|December 10, 2008
Apoptosis: a clinical perspectiveErnest C Borden, Harriet Kluger, John Crowley
The New England Journal of Medicine|September 26, 2008
Retraction: Barlogie et al. Duration of survival in patients with myeloma treated with thalidomide. N Engl J Med 2008;359:210-2Bart Barlogie, John D Shaughnessy, John Crowley
Journal of Health Communication|March 17, 2007
Pharmaceutical websites and the communication of risk informationJoel J Davis, Emily Cross, John Crowley
Pageof 18

Showing results (11-20 of 178) with videos related to

Sort By:
Pageof 18
Biometrics|July 14, 2005
Adaptive risk group refinementMichael LeBlanc, James Moon, John Crowley
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 8, 2010
Seamless phase I-II trial design for assessing toxicity and efficacy for targeted agentsAntje Hoering, Mike LeBlanc, John Crowley
Clinical Trials (London, England)|February 20, 2008
Interim futility analysis with intermediate endpointsBryan Goldman, Michael LeBlanc, John Crowley
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 28, 2008
Big question, small answerTony S K Mok, John Crowley
Current Oncology Reports|August 22, 2012
The automatic clinical trial: leveraging the electronic medical record in multisite cancer clinical trialsKeith Goodman, Judy Krueger, John Crowley
The New England Journal of Medicine|July 11, 2008
Duration of survival in patients with myeloma treated with thalidomideBart Barlogie, John D Shaughnessy, John Crowley
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 28, 2009
We probably have the answer: now what is the question?Peter Goldstraw, Ramón Rami-Porta, John Crowley
Nature Reviews. Drug Discovery|December 10, 2008
Apoptosis: a clinical perspectiveErnest C Borden, Harriet Kluger, John Crowley
The New England Journal of Medicine|September 26, 2008
Retraction: Barlogie et al. Duration of survival in patients with myeloma treated with thalidomide. N Engl J Med 2008;359:210-2Bart Barlogie, John D Shaughnessy, John Crowley
Journal of Health Communication|March 17, 2007
Pharmaceutical websites and the communication of risk informationJoel J Davis, Emily Cross, John Crowley
Pageof 18